Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 225 clinical trials
Featured trial
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma

therapy of ICS/LABA will be withdrawn during the 12week randomized treatment period and resumed at the end of the IMP treatment period, as outlined below: Screening period (4 weeks)

  • 06 Jan, 2023
  • 23 locations
Featured trial
EF-36/Keynote: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

This is a multicenter, single arm, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System concomitant with IV pembrolizumab (also known as MK-3475) in subjects previously untreated for their advance or metastatic intrathoracic, PD-L1 positive (TPS≥1% [tumor proportion score]) non-small cell lung …

  • 29 Nov, 2022
  • 1 location
Featured trial
Duke Clinical Rsearch Unit Research Volunteer Registry

Duke Clinical Rsearch Unit Research Volunteer Registry

  • 23 Nov, 2020
  • 1 location
SC IL-1Ra in SAH - Phase III Trial (SCIL) (SCIL)

, patients will be randomised to receive either IL-1Ra or placebo for a maximum of 21 days from onset of symptoms. Patients who are found to be non-aneurysmal following randomisation will be withdrawn from

  • 04 Jun, 2022
  • 12 locations
Open Label Randomized Clinical Trial to Assess the Safety of Teleconsultation

conducted on a per-protocol study sample, which will include all participants who have finished the study and have not been withdrawn because of non-allowed visits using modalities other than scheduled.

  • 01 Dec, 2021
  • 3 locations
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

will discontinue the targeted therapy and will be withdrawn from study and oriented towards standard treatments patients with a stable disease at 12 weeks will be randomized in order to

  • 22 Sep, 2021
  • 14 locations
Studies of Phlebotomy Therapy in Hereditary Hemochromatosis

This study will evaluate the effectiveness of a test called MCV in guiding phlebotomy (blood drawing) therapy in patients with hemochromatosis an inherited disorder that causes too much iron to be absorbed by the intestine. The excess damages body tissues, most severely in the liver, heart, pancreas and joints. Because …

Accepts healthy volunteers
  • 25 Oct, 2022
  • 1 location
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

This is a multi-center, double-blind, randomized, placebo-controlled, parallel-group phase 3 clinical study to confirm the safety and efficacy of T89 in patients with stable angina pectoris, with an extended open-label period to evaluate the long-term safety of T89. This study includes three main periods: the first study period is a …

  • 04 Mar, 2022
  • 1 location
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

"This is an international, multicenter, randomized, double-blind phase III study, plans to recruit 680 patients who received radical gastrectomy (R0, D2 or higher lymphadenectomy) with postoperative pathological stage II (T4aN0M0) or III (the 8th Edition American Joint Committee on Cancer [AJCC] Cancer Staging Manual) gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, …

  • 04 Oct, 2022
  • 25 locations
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV

  • 23 Jun, 2021
  • 1 location